Article

Targeting Brain Tumor Receptor Slows Glioblastoma Progression

Interfering with energetic metabolism may stop glioblastoma growth and recurrence.

Through a collaborative study, researchers examined the effects of a new inhibitor of PPARα in glioblastoma.

PPARα is a transcription factor known to be involved in the control of energetic metabolism. In a study published in the Journal of Cellular Physiology, researchers found that they could slow the growth of glioblastoma by blocking PPARα.

“Our studies point towards a possible way to counteract glioblastoma growth and recurrence by interfering with energetic metabolism by blocking PPARα,” said lead study author Annamaria Cimini.

The results of the study showed that when PPARα was blocked in glioblastoma, it caused a strong decrease in cell proliferation and migrations. Furthermore, it induced a high sensitivity to radiotherapy.

“The design of a new drug specifically directed against PPARα activity may provide new perspectives for glioblastoma therapies by counteracting its energy supply,” said Antonio Giordano, founder and director of the Sbarro Institute for Cancer Research and Molecular Medicine.

Related Videos
Anthony Perissinotti, PharmD, BCOP, discusses unmet needs and trends in managing chronic lymphocytic leukemia (CLL), with an emphasis on the pivotal role pharmacists play in supporting medication adherence and treatment decisions.
Image Credit: © alenamozhjer - stock.adobe.com
pharmacogenetics testing, adverse drug events, personalized medicine, FDA collaboration, USP partnership, health equity, clinical decision support, laboratory challenges, study design, education, precision medicine, stakeholder perspectives, public comment, Texas Medical Center, DNA double helix
pharmacogenetics challenges, inter-organizational collaboration, dpyd genotype, NCCN guidelines, meta census platform, evidence submission, consensus statements, clinical implementation, pharmacotherapy improvement, collaborative research, pharmacist role, pharmacokinetics focus, clinical topics, genotype-guided therapy, critical thought
Image Credit: © Andrey Popov - stock.adobe.com
Image Credit: © peopleimages.com - stock.adobe.com
TRUST-I and TRUST-II Trials Show Promising Results for Taletrectinib in ROS1+ NSCLC
World Standards Week 2024: US Pharmacopeia’s Achievements and Future Focus in Pharmacy Standards